Plexus Partners’ Post

How AI is transforming drug discovery 🧠💊 Pharmaceutical companies and start-ups are harnessing AI to improve speed and reduce costs at every stage of the drug discovery and development process. Read more ⬇️

Pharmaceutical companies and start-ups are harnessing AI to improve speed and reduce costs at every stage of the drug discovery and development process. #AI #drugdevelopment #pharma #drugdiscovery https://lnkd.in/e8RGYj8S

If you haven't heard the huge news already, Recursion announced its plan to acquire its smaller peer, Exscientia, for $688 million. This acquisition is part of Recursion's strategy to strengthen its position in the AI-powered drug discovery space. Exscientia, known for its expertise in using AI to design and develop new drugs, will complement Recursion's existing capabilities, potentially accelerating the development of novel therapies. This huge deal highlights the growing importance of AI integration in the pharmaceutical industry, as companies look to leverage technology to speed up drug discovery and reduce costs. #computationalchemistry #drugdiscovery #ai #machinelearning #biotechacquisition

AI can beat grandmasters at chess and outwit the world’s best at Go – but is it better than humans at coming up with new drugs? We speak to Dr Dave H. (Exscientia Chief Scientific Officer and Interim CEO) and Dr Alex Zhavoronkov (Insilico Medicine Founder and CEO) about their work revolutionising drug discovery: https://hubs.la/Q02vkX_q0 #artificialintelligence #AI #drugdiscovery #bioinformatics #computationalbiology #pharma #biotech Also mentioned: Sumitomo Pharma Co., Ltd., Sanofi, Bristol Myers Squibb, Merck Group, Bill & Melinda Gates Foundation, Relay Therapeutics, Nimbus Therapeutics, Healx, Google DeepMind

🌐 Exciting news for the #pharmaceuticalindustry in 2024! 💊 Ever wondered what groundbreaking developments are on the horizon? Dive into this article to uncover the game-changing advancements shaping the future of #pharma ! 🚀 🚀 Explore the innovations set to revolutionize the #pharmaceutical landscape in 2024. From cutting-edge treatments to transformative technologies, discover the dynamics that will redefine the industry! 🔍💡 📖 Read the full article here: https://buff.ly/3Obugqx 💬 Please share your thoughts in the comments below on which aspect of the pharmaceutical industry's future excites you the most. What are your predictions? Use the hashtags: #PharmaInnovation #FutureOfMedicine #HealthcareRevolution 📌 Follow our page for more updates and stay informed about the latest trends and breakthroughs in the pharmaceutical industry! 💊🌍

Connect with other Founders: https://lnkd.in/g2-KKmea Alphabet's Isomorphic Labs, led by CEO Sergei Yakneen, an AI-driven drug discovery startup, has secured deals with Eli Lilly and Novartis totaling nearly $3 billion. These collaborations aim to enhance Google DeepMind's AlphaFold AI technology, known for predicting protein structures in drug discovery. Eli Lilly's deal is valued at up to $1.5 billion, and Novartis's at up to $1.4 billion. Isomorphic's AI platform will be used for identifying and developing novel drug candidates, showcasing the potential to revolutionize the traditionally slow and expensive pharmaceutical development process. The timing of these deals, just before the J.P. Morgan Healthcare Conference, suggests Isomorphic's strategic move to solidify its position in drug discovery. Read more at: https://lnkd.in/gpmwjFjS

Unlocking the Future of Medicine with AI's Revolution in Drug Development and Discovery The advent of Artificial Intelligence (AI) has revolutionized many industries, with the pharmaceutical sector standing out as one of the most significant beneficiaries. AI's applications in drug development and discovery are vast, ranging from speeding up the process of finding new drugs to personalizing treatments for patients. This article delves into how AI is transforming the landscape of drug development and discovery and its key applications, benefits, and future prospects. #AI #Pharma #Biotech #Invesment #Nabil_Alhakamy https://lnkd.in/d8iG9vn9

Translating drug discoveries into commercially viable candidates remains a challenge for Australia's pharmaceutical industry, taking years and costing billions. This is where generative AI is changing the game. Gartner's Reuben Harwood, PhD explores further in Digital Nation Australia https://lnkd.in/e47bhiPU #GartnerIT #GenAI #GenerativeAI

Exciting news in the pharmaceutical industry! Gilead Sciences and Genesis Therapeutics have joined forces in a collaboration to develop innovative therapies using generative AI technology. Genesis’ GEMS platform will play a key role in creating and optimizing molecules for targets identified by Gilead, with Gilead having exclusive rights for clinical development and commercialization of resulting compounds. Genesis is tackling the challenge of limited training data for protein targets, leveraging their expertise in generative AI to expedite drug discovery for intricate targets. This partnership combines Genesis’ AI capabilities with Gilead’s extensive research and development background, promising advancements in the field. As part of the agreement, Genesis will receive upfront payments and stand to benefit from milestones and royalties. The collaboration is anticipated to have a notable impact on Gilead’s financial metrics, including a reduction in EPS, reflecting the strategic nature of this venture. Genesis Therapeutics stands out for its use of AI in generating and optimizing small molecule drug candidates. Their platform incorporates cutting-edge AI techniques like language and diffusion models, along with physical simulations. With substantial funding backing its AI-driven drug discovery initiatives, Genesis is at the forefront of innovation in the healthcare sector. For further details, check out the link: https://lnkd.in/gqd-UPWV Holly Edgar Colleen Byrd Jun Feng Advait Nagle

Our latest article, "PREDIT AI Success Story in Drug Discovery," is now live on ThinkML! In this piece, we delve into the remarkable success of Pharmaeconomica BV's PREDIT platform, an advanced AI tool that is revolutionizing the drug discovery process. PREDIT's innovative approach has led to the identification of potent cholinesterase inhibitors and antiviral compounds, showcasing its potential to accelerate research and development in the pharmaceutical industry. Discover how PREDIT is transforming the landscape of drug discovery by reducing timelines, enhancing precision, and uncovering new therapeutic opportunities. Check it out here: https://lnkd.in/dn-u9xcE #DrugDiscovery #AI #Innovation #Pharmaeconomica #PREDIT #CholinesteraseInhibitors #AntiviralCompounds #HealthcareInnovation #Biotech #Pharmaceuticals